These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma. Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100 [TBL] [Abstract][Full Text] [Related]
5. Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma. Martinez-Lopez J; Martinez-Sanchez P; Garcia-Sanz R; Sarasquete ME; Ayala R; Gonzalez M; Bautista JM; Gonzalez D; San Miguel J; Garcia-Effron G; Lahuerta JJ J Mol Diagn; 2006 Jul; 8(3):364-70. PubMed ID: 16825510 [TBL] [Abstract][Full Text] [Related]
6. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B; Yuan C; Dogan A; Stetler-Stevenson M; Marti GE Am J Hematol; 2014 Dec; 89(12):1159-60. PubMed ID: 25132630 [No Abstract] [Full Text] [Related]
7. [Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma]. Nihon Rinsho; 2016 Jul; 74 Suppl 5():565-9. PubMed ID: 30714704 [No Abstract] [Full Text] [Related]
8. Minimal residual disease detection in myeloma: no more molecular remissions? Rawstron AC Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557 [No Abstract] [Full Text] [Related]
9. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides. Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584 [TBL] [Abstract][Full Text] [Related]
11. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917 [TBL] [Abstract][Full Text] [Related]
12. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients. Vrabel D; Sedlarikova L; Besse L; Rihova L; Bezdekova R; Almasi M; Kubaczkova V; Brožová L; Jarkovsky J; Plonkova H; Jelinek T; Sandecka V; Stork M; Pour L; Sevcikova S; Hajek R Eur J Haematol; 2020 Mar; 104(3):190-197. PubMed ID: 31763708 [TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in multiple myeloma and acute leukaemia. Bakkus MH; Juge-Morineau N; van der Werff ten Bosch JE Med Oncol; 1996 Jun; 13(2):121-31. PubMed ID: 9013476 [TBL] [Abstract][Full Text] [Related]
14. Expression and mutation status of candidate kinases in multiple myeloma. Claudio JO; Zhan F; Zhuang L; Khaja R; Zhu YX; Sivananthan K; Trudel S; Masih-Khan E; Fonseca R; Bergsagel PL; Scherer SW; Shaughnessy J; Stewart AK Leukemia; 2007 May; 21(5):1124-7. PubMed ID: 17344920 [No Abstract] [Full Text] [Related]
15. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers. Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613 [TBL] [Abstract][Full Text] [Related]
16. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma. Quintero-Rivera F; El-Sabbagh Badr R; Rao PN Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276 [No Abstract] [Full Text] [Related]
17. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Nishihori T; Song J; Shain KH Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557 [TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions. Ho C; Arcila ME Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147 [TBL] [Abstract][Full Text] [Related]
19. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157 [TBL] [Abstract][Full Text] [Related]
20. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]